argenx Nears 2025 Report Amid VYVGART's Billion-Dollar Success

AMSTERDAM, the Netherlands – February 19, 2026 – Global immunology firm argenx is set to pull back the curtain on its full-year 2025 financial performance on February 26, an announcement keenly anticipated by investors and the biopharma industry. The upcoming conference call will not only detail fourth-quarter results but will also provide a crucial business update, capping a year of explosive growth for its flagship autoimmune therapy, VYVGART.

While the announcement itself is a routine financial disclosure, the context is anything but. The company is riding a wave of commercial success, having transformed from a promising biotech into a profitable commercial entity. Stakeholders will be scrutinizing the results for confirmation of VYVGART's continued market dominance, insight into the company's 2026 guidance, and progress updates on a deep pipeline that holds the key to its long-term ambition of reshaping autoimmune disease treatment.

The VYVGART Juggernaut: A Record-Breaking Year

The story of argenx in 2025 is inextricably linked to the stellar performance of VYVGART (efgartigimod). The neonatal Fc receptor (FcRn) blocker has not just met but consistently shattered expectations. The company entered the year with momentum, having posted approximately $2.2 billion in global net product sales in 2024, and accelerated from there.

Throughout 2025, quarterly reports painted a picture of remarkable growth. Product net sales grew from $790 million in the first quarter to an impressive $949 million in the second. The third quarter marked a historic milestone, with VYVGART sales surpassing $1 billion in a single quarter for the first time, reaching $1.13 billion. This represented a staggering 96% year-over-year increase and a 19% jump from the prior quarter, demonstrating sustained and accelerating demand.

This commercial success has been powered by several key factors. VYVGART has established itself as the leading biologic for generalized myasthenia gravis (gMG). Furthermore, its expansion into a second major indication, chronic inflammatory demyelinating polyneuropathy (CIDP), has opened up a significant new patient population. A critical growth driver has been the successful U.S. launch of VYVGART Hytrulo in a pre-filled syringe (PFS) format. This patient-friendly, subcutaneous option has been described as a “game-changer,” broadening the prescriber base and attracting new patients seeking greater convenience and independence. More than half of new patients starting on the PFS formulation were reportedly new to the VYVGART brand entirely.

This revenue surge has had a profound impact on the company's bottom line. After years of heavy investment in research and development, argenx has achieved profitability, reporting net incomes of $169 million, $245 million, and $344 million in the first three quarters of 2025, respectively. The upcoming report will confirm if the company successfully maintained this profitability for the full year, a major milestone for any commercial-stage biotech.

Eyes on Guidance and Market Leadership

As argenx prepares to address investors, attention will be squarely focused on the future. While the 2025 results are expected to be strong, the 2026 outlook and strategic commentary will be the main event. Analysts, who hold a consensus "Buy" rating on the stock, will be parsing the company’s revenue guidance for 2026 to see if the VYVGART growth trajectory can be maintained. Equally important will be the guidance on combined R&D and SG&A expenses, which were adjusted slightly upwards during 2025 to a range of $2.6 billion to $2.7 billion to support the product's rapid expansion and pipeline advancement.

Investors will also seek assurance of argenx's strategy to defend its leadership in the increasingly competitive FcRn inhibitor space. The company’s proactive approach to label expansion is its primary defense. A supplemental Biologics License Application (sBLA) for VYVGART in seronegative gMG is currently under Priority Review by the FDA, with a target action date of May 10, 2026. A positive decision would further solidify its dominance in the broader myasthenia gravis market.

Beyond gMG, the company has a packed schedule of catalysts. Topline results from the ADAPT OCULUS study in ocular MG are expected in the first half of 2026, with data from the ADVANCE-NEXT trial in primary immune thrombocytopenia (ITP) anticipated in the second half of the year. These readouts, along with others, are central to argenx's strategy of creating a multi-indication blockbuster.

Building the Future: Pipeline Progress and Vision 2030

Beyond VYVGART's immediate success, the February 26th update will provide a progress report on the company's ambitious "Vision 2030." This long-term plan aims to treat 50,000 patients across 10 labeled indications and advance five new pipeline candidates into late-stage development. The upcoming call will be a litmus test for the execution of this vision.

Key pipeline updates will be a major focus. The company has five registrational study readouts for efgartigimod planned for 2026 alone, targeting conditions like myositis, thyroid eye disease (TED), and multifocal motor neuropathy (MMN). Success in even a fraction of these would significantly expand VYVGART's addressable market and cement its franchise status.

Investors will also look for updates on the next generation of potential therapies. This includes empasiprubart, which is advancing in studies for MMN and delayed graft function (DGF), and ARGX-119, which is moving toward a registrational study in congenital myasthenic syndrome (CMS) following positive proof-of-concept data. Furthermore, argenx has been advancing four new molecules into Phase 1 trials—ARGX-213, ARGX-121, ARGX-109, and ARGX-220—representing the next wave of innovation from its Immunology Innovation Program. Progress reports on these early-stage assets are crucial for demonstrating the long-term sustainability of the company's growth model.

The autoimmune disease landscape is highly dynamic, characterized by intense innovation and a push toward more patient-centric solutions. argenx's strategy—combining a best-in-class commercial product with a robust, multi-asset pipeline and strategic partnerships to access new technologies like oral peptides—positions it as a formidable player. The upcoming financial report will offer the clearest picture yet of how effectively the company is leveraging its current success to build an enduring immunology powerhouse. The February 26th report will therefore be a critical indicator of whether the company's ambitious strategy is poised to redefine the standard of care for a host of debilitating autoimmune conditions.